TY - JOUR
T1 - Primary refractory multiple myeloma
T2 - a real-world experience with 85 cases
AU - Jurczyszyn, Artur
AU - Waszczuk-Gajda, Anna
AU - Castillo, Jorge J.
AU - Krawczyk, Katarzyna
AU - Stork, Martin
AU - Pour, Ludek
AU - Usnarska-Zubkiewicz, Lidia
AU - Potoczek, Stanisław
AU - Hus, Iwona
AU - Davila Valls, Julio
AU - Hari, Parameswaran
AU - Chhabra, Saurabh
AU - Gentile, Massimo
AU - Mikala, Gabor
AU - Varga, Gergely
AU - Chim, Chor Sang
AU - Fiala, Mark
AU - Vij, Ravi
AU - Schutz, Natalia
AU - Rodzaj, Marek
AU - Porowska, Agnieszka
AU - Vesole, David H.
AU - Druzd-Sitek, Agnieszka
AU - Walewski, Jan
AU - Nooka, Ajay K.
N1 - Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/12
Y1 - 2020/12
N2 - This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.
AB - This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.
KW - Double-refractory multiple myeloma
KW - prognosis
KW - survival
KW - treatment response
UR - https://www.scopus.com/pages/publications/85087612188
U2 - 10.1080/10428194.2020.1788014
DO - 10.1080/10428194.2020.1788014
M3 - Article
C2 - 32623944
AN - SCOPUS:85087612188
SN - 1042-8194
VL - 61
SP - 2868
EP - 2875
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 12
ER -